Opioid use disorder (OUD) is a chronic brain condition defined by compulsive use of prescription or illicit opioids despite escalating harm, driven by lasting changes to reward, stress, and self-control circuits. About 8.9 million Americans aged 12 and older met DSM-5-TR criteria for OUD in 2022 (SAMHSA NSDUH), and US opioid-involved overdose deaths exceeded 81,000 in 2023, three-quarters driven by illicitly manufactured fentanyl.

Opioid use disorder (ICD-10: F11.10-F11.99) is the DSM-5-TR diagnosis covering problematic use of any opioid — prescription analgesics (oxycodone, hydrocodone, morphine), heroin, or synthetic opioids (fentanyl, methadone). Diagnosis requires 2 or more of 11 criteria within 12 months: opioids taken in larger amounts or longer than intended, persistent desire or unsuccessful efforts to cut down, large time spent obtaining/using/recovering, craving, role failure, interpersonal problems, giving up activities, hazardous use, continued use despite harm, tolerance, and withdrawal. Severity is graded mild (2-3), moderate (4-5), or severe (6+). Tolerance and withdrawal from appropriately prescribed opioids alone, in patients without other criteria, do not constitute OUD.
The key symptoms of Opioid Use Disorder are: Taking opioids in larger amounts or over a longer period than was intended, including running out of a prescription early on most refill cycles., Persistent desire or repeated unsuccessful attempts to cut down or control opioid use, often described as 'every Monday I tell myself I'll stop'., Spending a great deal of time obtaining opioids, using them, or recovering from their effects — sometimes much of the waking day., Strong cravings or urges to use opioids, often triggered by physical pain, emotional distress, drug paraphernalia, or specific people and locations., Recurrent opioid use leading to failure to fulfill obligations at work, school, or home — missed shifts, missed appointments, missed parenting., Continued opioid use despite persistent or recurrent social or interpersonal problems caused or worsened by the substance., Important social, occupational, or recreational activities are given up or reduced because of opioid use..
Diagnosis is clinical, based on DSM-5-TR interview confirming 2 or more of 11 criteria within 12 months. Universal screening should occur in primary care, emergency departments, prenatal care, and addiction settings. Validated screening tools include the Tobacco, Alcohol, Prescription medications, and other Substance use (TAPS) tool, the Opioid Risk Tool (ORT) before prescribing, and the Drug Abuse Screening Test (DAST-10). Urine drug screening is supportive — useful to identify undisclosed opioid use, monitor adherence to prescribed buprenorphine or methadone, and detect adulterants — but immunoassay panels often miss fentanyl, methadone, and buprenorphine without specifically ordered confirmation testing. The Clinical Opioid Withdrawal Scale (COWS) quantifies acute withdrawal severity in patients presenting with cessation: scores 5-12 mild, 13-24 moderate, 25-36 moderately severe, 37+ severe. Buprenorphine induction is typically initiated when COWS ≥8 to avoid precipitated withdrawal. Risk-stratification for overdose requires assessment of route (injection vs oral), fentanyl exposure, polysubstance use (alcohol, benzodiazepines, stimulants), recent abstinence (tolerance loss), and access to naloxone. Always assess co-occurring psychiatric disorders, infectious complications (HIV, hepatitis C, endocarditis), and chronic pain. Distinguish OUD from physical dependence in legitimate chronic pain patients — dependence alone does not constitute disorder if no other DSM-5-TR criteria are met.
OUD is a chronic relapsing condition with outcomes comparable to type 2 diabetes when treated with medication. On methadone or buprenorphine, all-cause mortality falls by approximately 50%, overdose mortality by 60-80%, and HIV and hepatitis C transmission decline substantially. One-year retention in MOUD is 40-70% in well-run programs; many patients require multiple treatment episodes before achieving sustained stability. Lifetime prognosis is heavily influenced by access to medication: in regions where MOUD is widely available, mortality approaches population-typical levels; where access is restricted, OUD remains among the leading causes of premature death in adults aged 18-50. Untreated OUD carries 10-fold higher all-cause mortality than the general population (Hser 2017 cohort study), driven by overdose, infectious disease, cardiovascular events, and suicide. Long-term continuation of medication is recommended; tapering off after sustained remission raises 12-month relapse risk approximately 4-fold and is rarely indicated outside special circumstances.
An addiction medicine specialist, addiction psychiatrist, or specialized program should be involved for moderate-to-severe OUD, fentanyl-era buprenorphine induction, pregnancy with OUD, co-occurring psychiatric or infectious disorders, recent overdose, recent incarceration, or methadone access. Primary care can effectively manage stable OUD with buprenorphine now that the MAT Act 2022 has removed the X-waiver — but every primary care clinician should be ready to refer urgently and to prescribe take-home naloxone universally.
Find specialists →Acute withdrawal peaks at 36-72 hours after the last opioid dose and resolves over 5-10 days with appropriate management. Post-acute withdrawal — anhedonia, sleep disturbance, irritability, craving — persists for 4-12 weeks. Cognitive recovery continues over 6-18 months. Once stabilized on methadone or buprenorphine, most patients describe a 'return to normal life' within 4-12 weeks. Hepatic and renal function generally normalize within 8-12 weeks. Long-term remission requires ongoing medication and behavioral support; the steepest reduction in relapse risk occurs during years 2-5 of sustained engagement.
Regular aerobic exercise improves mood, sleep, and constipation — three of the most common chronic complaints in OUD recovery. Aim for 150 minutes per week of moderate activity, with 2-3 sessions of strength training. Group classes can substitute for the social rituals previously built around using. Avoid high-intensity exertion in the first 3-5 days of withdrawal due to autonomic instability.
Look for board certification in addiction medicine or addiction psychiatry, willingness to prescribe both buprenorphine and naltrexone, ready linkage to a methadone program when needed, and harm-reduction services on-site (naloxone distribution, syringe exchange referral, fentanyl test strips). Continuity matters — OUD recovery is a multi-year process. Ask whether the practice can also provide hepatitis C treatment, infectious-disease screening, and mental health care, or refers in a coordinated way.
Medically reviewed by AIHealz Medical Editorial Board · May 13, 2026
Ranked by patient outcomes and specialized experience.
Verifying top specialists in Mexico.
Apply as specialist →Specialists who treat Opioid Use Disorder. Get expert guidance and personalized care.